医药市场新风向：石家庄四药多款药品通过一致性评价，含两款热销注射液

Core Insights - Shijiazhuang Four Pharmaceutical has received approval for two injectable products: heavy tartrate norepinephrine injection and isoprenaline injection, both considered essential and have passed consistency evaluation [2][4] Group 1: Product Approval and Market Performance - Heavy tartrate norepinephrine injection is a critical drug used for treating low blood pressure due to various medical conditions, with a reported sales figure exceeding 1.5 billion yuan in the 2023 national hospital market [2][4] - Isoprenaline injection is utilized for treating acute spasmodic pain related to gastrointestinal and biliary dysfunction, with sales surpassing 800 million yuan in 2023, reflecting a year-on-year growth of 11.08% [7] Group 2: Competitive Landscape - Prior to the approval, heavy tartrate norepinephrine injection had production licenses held by 12 companies, with 32 more under review, including Shijiazhuang Four Pharmaceutical and others [6] - For isoprenaline injection, 27 companies held production licenses, with 38 companies, including Hunan Kelun Pharmaceutical and Shandong New Era Pharmaceutical, currently under review for production [9]